Lenalidomide Plus Prednisone Results in Durable Clinical, Histopathologic, and Molecular Responses in Patients With Myelofibrosis | Zendy

Alfonso QuintásCardama | Zendy; Hagop M. Kantarjian | Zendy; Taghi Manshouri | Zendy; Deborah A. Thomas | Zendy; Jorge E. Cortés | Zendy; Farhad Ravandi | Zendy; Guillermo GarciaManero | Zendy; Alessandra Ferrajoli | Zendy; Carlos E. BuesoRamos | Zendy; Srđan Verstovšek | Zendy

Open Access

Lenalidomide Plus Prednisone Results in Durable Clinical, Histopathologic, and Molecular Responses in Patients With Myelofibrosis

Author(s) -

Alfonso QuintásCardama,

Hagop M. Kantarjian,

Taghi Manshouri,

Deborah A. Thomas,

Jorge E. Cortés,

Farhad Ravandi,

Guillermo GarciaManero,

Alessandra Ferrajoli,

Carlos E. BuesoRamos,

Srđan Verstovšek

Publication year - 2009

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2009.22.6548

Subject(s) - medicine , myelofibrosis , lenalidomide , prednisone , gastroenterology , adverse effect , anemia , neutropenia , surgery , tolerability , chemotherapy , bone marrow , multiple myeloma

To investigate the safety and efficacy of the combination of lenalidomide and prednisone in patients with myelofibrosis (MF).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog